Is dupixent for asthma?

Is Dupixent approved for asthma?

Dupixent (dupilumab) received FDA approval in 2018 for moderate-to-severe asthma in people aged 12 and older whose asthma is not controlled by inhaled corticosteroids. It is also approved for children as young as 6 when standard treatments fall short.

How does it work in asthma?

Dupixent blocks two proteins, IL-4 and IL-13, that drive type 2 inflammation. By interrupting these signals it reduces airway swelling, mucus production, and the frequency of asthma attacks. Clinical trials showed a 46-67 % drop in severe exacerbations compared with placebo.

Who is most likely to benefit?

Patients with high blood eosinophils (≥150 cells/µL) or elevated FeNO levels usually see the largest improvement. People whose asthma is driven by allergic triggers or comorbid conditions such as atopic dermatitis or chronic rhinosinusitis with nasal polyps often gain added relief from one drug that targets several of these diseases.

Can it replace inhaled steroids?

No. Guidelines recommend continuing background inhaled corticosteroid therapy. Dupixent is added for patients who still have symptoms or need frequent oral steroids despite optimized inhalers.

What side effects are patients asking about?

The most common reactions are injection-site redness, conjunctivitis, and cold-like symptoms. Rare cases of eosinophilic pneumonia or serum-sickness-like reactions have been reported, so any new breathing difficulty or rash should be evaluated promptly.

When does the patent expire and are biosimilars coming?

The main composition-of-matter patent listed on DrugPatentWatch.com expires in 2031, with some formulation patents extending to 2034. No approved biosimilars are on the market yet, though several companies have started Phase 3 trials.

How does Dupixent compare with other biologics?

- Versus omalizumab (anti-IgE): Dupixent works in a broader group of patients and does not require an IgE blood test.
- Versus benralizumab or mepolizumab (anti-IL-5): Dupixent lowers both eosinophils and airway inflammation driven by IL-4/IL-13, which can improve nasal and skin symptoms at the same time.
- Dosing convenience: every two weeks subcutaneous injection versus monthly or more frequent infusions for some competitors.

What happens if I stop Dupixent?

Studies show lung function and exacerbation rates begin to worsen within weeks to months after stopping. Most patients who respond keep using it long-term unless side effects or insurance issues intervene.

[1] https://www.drugpatentwatch.com/drug/dupixent